PATENT CLAIM ANALYSIS

Application Number: 16209206
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "04400A"]

Abstract:
A method of treating a patient having an elevated inflammatory response, such as an elevated Type I interferon response, is provided. The method can be used to treat sepsis. The method comprises administering to a patient having an elevated inflammatory response, an inhibitor of anaplastic lymphoma kinase (ALK inhibitors) or expression of ALK, in an amount effective to treat the elevated inflammatory response.

Claim (Index 10):
The method of  claim 1 , wherein the inflammatory disease or condition is:\n systemic inflammatory response syndrome; meningococcemia; trauma hemorrhage; ionizing radiation exposure; acute pancreatitis; adult respiratory distress syndrome (ARDS); reperfusion injury, which includes: post-pump syndrome or ischemia-reperfusion injury; cardiovascular disease, which includes: cardiac stun syndrome, myocardial infarction, or congestive heart failure; infectious disease, which includes: hiv infection/hiv neuropathy, meningitis, hepatitis, septic arthritis, peritonitis, pneumonia epiglottitis, or  E. coli  0157:H7; hemolytic uremic syndromic/thrombolytic thrombocytopenic purpura; malaria; dengue hemorrhagic fever; leishmaniasis; leprosy; toxic shock syndrome; streptococcal myositis; gas gangrene;  Mycobacterium tuberculosis; Mycobacterium avium intracellulare; Pneumocystis carinii  pneumonia; pelvic inflammatory disease; orchitis/epidydimitis;  Legionella ; lyme disease; influenza A; Epstein-Barr virus; viral associated hemiaphagocytic syndrome; viral encephalitis/aseptic meningitis; obstetric or gynecological conditions, including: premature labor, miscarriage, or infertility; inflammatory disease or autoimmune conditions, which includes: rheumatoid arthritis/seronegative arthropathies, osteoarthritis, inflammatory bowel disease, systemic lupus erythematosis, iridoeyelitis/uveitistoptic neuritis, idiopathic pulmonary fibrosis, systemic vasculitis/Wegener's gramilornatosis, sarcoidosis, or orchitis/vasectomy reversal procedures; allergic/atopic diseases, which includes: asthma, allergic rhinitis, eczema, allergic contact dermatitis, allergic conjunctivitis, or hypersensitivity pneumonitis; transplant-related conditions, including: organ transplant rejection or graft-versus-host disease; cachexia; congenital conditions, which include: cystic fibrosis, familial hematophagocytic lymphohistiocytosis or sickle cell anemia; dermatologic conditions, which includes: psoriasis and alopecia; neurologic, which includes: multiple sclerosis and migraine headache; renal conditions, which includes: nephrotic syndrome, hermodialysis, and uremia; toxicity, which includes: OKT3 therapy, anti-CD3 therapy, cytokine therapy, chemotherapy, radiation therapy, or chronic salicylate intoxication; or metabolic/idiopathic conditions, which include: wilson's disease, hemachromatosis, alpha-1 antitrypsin deficiency, diabetes, Hashimoto's thyroiditis, osteoporosis, hypothalamic-pituitary-adrenal axis evaluation, or primary biliary cirrhosis.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 98.0
- Lexical Diversity: 1.67442
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15241821', '15109945', '15028813', '15564995', '15483645']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8002862039945636
- 35 USC 102 Novelty (BERT): 0.5292021809280061
- Combined Prediction Score: 0.7731778016879078
- Mean Citation Score: 291.430466
- Max Citation Score: 324.42
- Similarity Product: 202.1851570165157

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test